To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients with COVID19 not requiring Invasive Mechanical Ventilation [IMV], are: a)more effective in preventing clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: 1.Death2.Acute Myocardial Infarction [AMI]3.Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]4.Need of either: a.Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) orb.IMV in patients who at randomisation were receiving standard oxygen therapy5.IMV in patients who at randomisation were receiving non-invasive mechanical ventilationb)Similar in terms of major bleeding risk TRIAL DESIGN: Multicentre, randomised controlled, superiority, open label, parallel group, two arms (1:1 ratio), in-hospital study.

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol / Marietta, M; Vandelli, P; Mighali, P; Vicini, R; Coluccio, V; D'Amico, R; Aschieri, D; Brugioni, L; Clini, E; Codeluppi, M; Imberti, D; Magnacavallo, A; Meschiari, M; Mussini, C; Orlando, S; Pinelli, G; Pietrangelo, A; Sarti, L; Silva, M.. - In: TRIALS. - ISSN 1745-6215. - 21:1(2020), pp. 1-5. [10.1186/s13063-020-04475-z]

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol

Vicini, R;Coluccio, V;D'Amico, R;Clini, E;Mussini, C;Orlando, S;Pietrangelo, A;
2020

Abstract

To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients with COVID19 not requiring Invasive Mechanical Ventilation [IMV], are: a)more effective in preventing clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: 1.Death2.Acute Myocardial Infarction [AMI]3.Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]4.Need of either: a.Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) orb.IMV in patients who at randomisation were receiving standard oxygen therapy5.IMV in patients who at randomisation were receiving non-invasive mechanical ventilationb)Similar in terms of major bleeding risk TRIAL DESIGN: Multicentre, randomised controlled, superiority, open label, parallel group, two arms (1:1 ratio), in-hospital study.
2020
26-giu-2020
21
1
1
5
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol / Marietta, M; Vandelli, P; Mighali, P; Vicini, R; Coluccio, V; D'Amico, R; Aschieri, D; Brugioni, L; Clini, E; Codeluppi, M; Imberti, D; Magnacavallo, A; Meschiari, M; Mussini, C; Orlando, S; Pinelli, G; Pietrangelo, A; Sarti, L; Silva, M.. - In: TRIALS. - ISSN 1745-6215. - 21:1(2020), pp. 1-5. [10.1186/s13063-020-04475-z]
Marietta, M; Vandelli, P; Mighali, P; Vicini, R; Coluccio, V; D'Amico, R; Aschieri, D; Brugioni, L; Clini, E; Codeluppi, M; Imberti, D; Magnacavallo, A; Meschiari, M; Mussini, C; Orlando, S; Pinelli, G; Pietrangelo, A; Sarti, L; Silva, M.
File in questo prodotto:
File Dimensione Formato  
Marietta (COVID-19 HD Modena randomised trial- 2020).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 233.75 kB
Formato Adobe PDF
233.75 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1204467
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 33
social impact